Copyright
Wanrudee Isaranuwatchai; Rachel A. Archer; Yot Teerawattananon; Anthony J. CulyerPublished On
2019-12-12ISBN
Language
- English
Print Length
214 pages (xxx+184)Dimensions
Weight
Media
OCLC Number
1132418494LCCN
2019452971BIC
- MB
- MBNH
- MBN
BISAC
- MED000000
- MED022000
- MED076000
LCC
- RA441
Keywords
- Non-communicable diseases
- NCDs
- death
- practical guidelines
- Prince Mahidol Award Conference
- PMAC
Non-communicable Disease Prevention
Best Buys, Wasted Buys and Contestable Buys
- Wanrudee Isaranuwatchai (editor)
- Rachel A. Archer (editor)
- Yot Teerawattananon (editor)
- Anthony J. Culyer (editor)
Non-communicable diseases (NCDs) are the leading cause of death worldwide, contributing to over 73% of all deaths annually. Each day NCDs cause more than 100,000 deaths, 80% of which occur in low- and middle-income countries. NCDs, however, are largely preventable, and a great deal of technical knowledge exists about how to prevent and manage them. Why, then, have we, as a global community, not been more successful at reducing this NCD burden? Does a universal problem not have a universal solution?
Created by an international consortium of experts, this informative and accessible book provides practical guidelines, key learning points, and dynamic, real-world case studies to aid NCD program managers, policy officers and decision-makers in low- and middle-income countries, so that they can assess interventions for the prevention and control of NCDs.
The book was commissioned by the Prince Mahidol Award Conference (PMAC), an annual international conference centred on policy of global significance related to public health. NCD Prevention: Best Buys, Wasted Buys and Contestable Buys emphasises the importance of context in NCD control and prevention, arguing that the success of an intervention lies in an ability to respond to local needs and environments. The book comprises ten chapters, which collectively explore the reasons behind, and strategies for, preventing and managing the NCD burden. It spans key themes such as political economy, the transferability of economic evidence, the role of cross-sectoral policies, the importance of deliberative processes, and health technology assessment.
This book is written for the benefit of the global health community, and is primarily targeted at those individuals who are involved in NCD programs. This book will also be of interest to NCD champions, policy advocates, and educators spearheading the movement for increased visiblity of NCDs.
Additional Resources
Interview Guide NCD Managers
Analysis of the Global Health Cost Effectiveness Analysis Registry
Analysis of the Global Health Cost Effectiveness Analysis Registry (2)
Analysis of the 47 case studies on evidence use and additional considerations
The Transferability of Economic Evaluations Across Settings
Methods of Umbrella Review
Contents
1. Introduction
(pp. 1–16)- Wanrudee Isaranuwatchai
- Rachel A. Archer
- Anthony Culyer
- Sumithra Krishnamurthy Reddiar
- Jesse B. Bump
- Yot Teerawattananon
- Alia Luz
- Manushi Sharma
- Waranya Rattanavipapong
4. Best Buys
(pp. 51–70)- Tazeem Bhatia
- Ryota Nakamura
- Arisa Shichijo
5. Wasted Buys
(pp. 71–90)- Yot Teerawattananon
- Manushi Sharma
- Alia Luz
- Waranya Rattanavipapong
- Adam G. Elshaug
- David D. Kim
- Rachel L. Bacon
- Peter J. Neumann
7. Finding the Best Evidence
(pp. 119–128)- Thunyarat Anothaisintawee
8. Cross-Sectoral Policies to Address Non-Communicable Diseases
(pp. 129–146)- Melitta Jakab
- Peter Smith
9. Deliberative Processes in Decisions about Best Buys, Wasted Buys, and Contestable Buys: Uncertainty and Credibility
(pp. 147–170)- Kalipso Chalkidou
- Anthony Culyer
10. Summing up
(pp. 171–174)- Wanrudee Isaranuwatchai
- Rachel A. Archer
- Anthony Culyer
Contributors
Wanrudee Isaranuwatchai
(editor)Wanrudee Isaranuwatchai, Ph.D., is a Senior Researcher at the Health Intervention and Technology Assessment Program (a part of the Ministry of Public Health) in Bangkok, Thailand, a Director at the Centre for Excellence in Economic Analysis Research of St. Michael's Hospital and a Senior Health Economist at the Canadian Centre for Applied Research in Cancer Control in Canada. She is also an Assistant Professor at the Institute of Health Policy, Management and Evaluation, University of Toronto. Her research focuses on how to apply economic evaluation in the real world setting as well as how to advance methods in economic evaluation. She has experience conducting economic evaluations using person-level data and decision modelling. She has collaborated with researchers and decision-makers in various areas to help communicate the value of health initiatives using economic evidence. Dr. Isaranuwatchai is dedicated to promoting the use of evidence in healthcare decision making.
Rachel A. Archer
(editor)Rachel A. Archer, M.P.H., is a Project Associate at the Health Intervention and Technology Assessment Program (HITAP). Her work focuses on health system strengthening and supporting evidence-informed health policy making in low- and middle-income countries (LMICs). She is the focal point at HITAP for the Total Systems Effectiveness (TSE) project, an approach to strengthen vaccine decision-making in LMICs, and she currently leads the PMAC Commissioned Work project. Rachel has also supported capacity-building activities for Indonesia, Kenya and The Philippines. Rachel holds a Master's degree in Public Health from the University of Sheffield and a Bachelor of Arts in International Development from the University of Leeds. Whilst studying, she interned with various non-profit organizations across East and West Africa. For her Master's thesis, Rachel collaborated with a non-profit to investigate the trend towards teenage pregnancy in Luwero District, Uganda, through an intersectional framework. She was awarded the Carpenter Prize for Best Dissertation.
Yot Teerawattananon
(editor)Yot Teerawattananon, MD., Ph.D., is the founding leader of the Health Intervention and Technology Assessment Program (HITAP), which is a semi-autonomous research institute of Thailand's Ministry of Public Health. The works of HITAP have been used to inform policy decisions regarding the adoption of medicines, medical devices, health promotion and disease prevention programmes under the Universal Health Coverage Scheme and the national pharmaceutical reimbursement list, the National List of Essential Medicines. Recently, he joins the National University of Singapore as a visiting professor at Saw Swee Hock School of Public Health as well as is the Executive Board of the international Decision Support Initiative (iDSI). He has published more than 140 peer-reviewed journal articles and provided technical support on HTA capacity building in Asia and Africa. He is also one of the founders of HTAsiaLink, a regional network comprising governmental health technology assessment agencies in the Asia and Pacific region.
Anthony J. Culyer
(editor)Anthony J. Culyer, Ph.D., is Emeritus Professor of Economics at the University of York (England), Senior Fellow at the Institute of Health Policy, Management and Evaluation at the University of Toronto (Canada) and Visiting Professor at Imperial College London. He is Chair of the Board of the international Decision Support Initiative (iDSI). He was the founding Organizer of the Health Economists' Study Group. For thirty-three years he was the founding Co-Editor, with Joe Newhouse at Harvard, of Journal of Health Economics. He was founding Vice Chair of the National Institute for Health and Care Excellence (NICE) until 2003. He is Editor-in-Chief of the online Encyclopaedia of Health Economics. For many years he was chair of the Department of Economics & Related Studies at York and, for six of them, was also deputy vice-chancellor. He has published widely, mostly in health economics.He is a Founding Fellow of the Academy of Medical Sciences, an Honorary Fellow of the Royal College of Physicians of London and an Honorary Member of the Finnish Society for Health Economics (2013). He holds an honorary doctorate from the Stockholm School of Economics and is a Commander of the British Empire (CBE). He has been a member or chaired many policy committees and boards in the UK and Canada including authoring the 1994 reforms of NHS Research and Development and being a director of the Canadian Agency for Drugs and Technologies in Health (CADTH).